Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data

Basit Öğe Kaydı
dc.authoridErden, Abdulsamet/0000-0002-8084-2018
dc.authoridKanıtez, Nilüfer Alpay/0000-0003-1185-5816
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.authoridBilgin, Emre/0000-0002-2260-4660
dc.authoridGonullu, Emel/0000-0002-6990-4206
dc.authoridIlgen, Ufuk/0000-0001-6443-6426
dc.authoridKaradag, Omer/0000-0002-3443-3117
dc.authorwosidErden, Abdulsamet/W-2397-2019
dc.authorwosidKOCA, SULEYMAN SERDAR/HJY-2666-2023
dc.authorwosidYazisiz, Veli/C-1808-2016
dc.authorwosidKanıtez, Nilüfer Alpay/W-7332-2019
dc.authorwosidkucuksahin, orhan/GZA-3287-2022
dc.authorwosidYağız, Burcu/JQW-5031-2023
dc.authorwosidBilgin, Emre/C-8092-2015
dc.contributor.authorKimyon, G.
dc.contributor.authorKalyoncu, U.
dc.contributor.authorKiraz, S.
dc.contributor.authorBes, C.
dc.contributor.authorCoskun, N.
dc.contributor.authorYagiz, B.
dc.contributor.authorKucuksahin, O.
dc.date.accessioned2024-06-12T11:07:36Z
dc.date.available2024-06-12T11:07:36Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). Methods The TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test). Results Of 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups. Conclusion LEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.en_US
dc.description.sponsorshipHacettepe Rheumatology Societyen_US
dc.description.sponsorshipthis study was funding by Hacettepe Rheumatology Society. Competing interests: see page 858.en_US
dc.identifier.endpage858en_US
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue4en_US
dc.identifier.pmid32896266en_US
dc.identifier.startpage852en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22090
dc.identifier.volume39en_US
dc.identifier.wosWOS:000691869100019en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.ispartofClinical And Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLeflunomideen_US
dc.subjectMethotrexateen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectBiologic Or Targeted-Synthetic Dmardsen_US
dc.subjectCombinationen_US
dc.subjectTherapyen_US
dc.subjectManagementen_US
dc.subjectMonotherapyen_US
dc.titleBiological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective dataen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu